# EDGAR Filing Document

**Accession Number:** 0001796280
**File Stem:** 0001586894-25-000005
**Filing Date:** 2025-12
**Character Count:** 7401
**Document Hash:** 43629de461c7d5c4803b14b2c0db4198
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001586894-25-000005.hdr.sgml**: 20251217

**ACCESSION NUMBER**: 0001586894-25-000005

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251215

**FILED AS OF DATE**: 20251217

**DATE AS OF CHANGE**: 20251217

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Multani Pratik S
- **CENTRAL INDEX KEY:** 0001586894

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39269
- **FILM NUMBER:** 251580924

**MAIL ADDRESS:**
- **STREET 1:** C/O FATE THERAPEUTICS, INC.
- **STREET 2:** 3535 GENERAL ATOMICS COURT, SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Oric Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001796280
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 471787157
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 240 E. GRAND AVE.
- **STREET 2:** 2ND FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 388-5600

**MAIL ADDRESS:**
- **STREET 1:** 240 E. GRAND AVE.
- **STREET 2:** 2ND FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Multani Pratik S<br><sub>(Last) (First) (Middle)</sub><br>C/O ORIC PHARMACEUTICALS, INC.<br>240 E. GRAND AVE., 2ND FLOOR<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Medical Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Oric Pharmaceuticals, Inc. [ ORIC ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-12-15 |  | M |  | 29333 | A | 0<sup>(1)</sup> | 78869<sup>(2)</sup> | D |  |
| Common Stock | 2025-12-16 |  | S<sup>(3)</sup> |  | 10720 | D | 9.0605<sup>(4)</sup> | 68149 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(1)</sup> | 2025-12-15 |  | M |  |  | 8000 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 8000 | $0 | 0 | D |  |
| Restricted Stock Unit | <sup>(1)</sup> | 2025-12-15 |  | M |  |  | 10000 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 10000 | $0 | 10000 | D |  |
| Restricted Stock Unit | <sup>(1)</sup> | 2025-12-15 |  | M |  |  | 11333 | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 11333 | $0 | 22667 | D |  |

---

### Footnotes:

(1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

(2) Includes an aggregate of 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.

(3) Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.

(4) Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0449 to $9.1451 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

(5) 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.

(6) 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.

(7) 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

**Signature:** /s/ Christian Kuhlen, attorney-in-fact  
**Date:** 2025-12-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**